Biotech News

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November

Foghorn Therapeutics (FHTX)Foghorn TherapeuticsCompany update

WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines against challenging targets in oncology and immunology & inflammation, today announced that management will participate in the Guggenheim Third

Related news

Foghorn Therapeutics

Foghorn Therapeutics is an oncology company focused on chromatin biology and gene-regulation targets. Its platform seeks to create differentiated cancer therapies through epigenetic control.

Recent company news

Stock data

Close
1.78 USD
Market cap
213.13M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States